| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Global cancer statistics, 2012.
|
CA Cancer J Clin
|
2015
|
53.52
|
|
2
|
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
|
N Engl J Med
|
2004
|
25.68
|
|
3
|
Cancer statistics in China, 2015.
|
CA Cancer J Clin
|
2016
|
12.92
|
|
4
|
Chemotherapy with preoperative radiotherapy in rectal cancer.
|
N Engl J Med
|
2006
|
12.50
|
|
5
|
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
|
J Clin Oncol
|
2006
|
7.05
|
|
6
|
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
|
J Clin Oncol
|
2009
|
5.69
|
|
7
|
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
|
N Engl J Med
|
2014
|
4.81
|
|
8
|
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
|
Lancet Oncol
|
2012
|
3.12
|
|
9
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2012
|
3.02
|
|
10
|
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.45
|
|
11
|
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
|
Lancet Oncol
|
2010
|
1.97
|
|
12
|
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2014
|
1.79
|
|
13
|
Population-based assessment of the surgical management of locally advanced colorectal cancer.
|
J Natl Cancer Inst
|
2006
|
1.66
|
|
14
|
Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients.
|
Ann Surg
|
2002
|
1.51
|
|
15
|
Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.
|
Colorectal Dis
|
2013
|
1.49
|
|
16
|
Multivisceral resection for colon carcinoma.
|
Dis Colon Rectum
|
2009
|
1.15
|
|
17
|
Extended resection for locally advanced colorectal carcinoma.
|
Am J Surg
|
1992
|
1.11
|
|
18
|
Extended resections for carcinoma of the colon and rectum.
|
Surg Gynecol Obstet
|
1985
|
0.99
|
|
19
|
Chemotherapy has also an effect on primary tumor in colon carcinoma.
|
Ann Surg Oncol
|
2008
|
0.89
|
|
20
|
Neo-adjuvant chemoradiotherapy and multivisceral resection to optimize R0 resection of locally recurrent adherent colon cancer.
|
Eur J Surg Oncol
|
2014
|
0.88
|
|
21
|
Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience.
|
Eur J Surg Oncol
|
2012
|
0.87
|
|
22
|
MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.83
|
|
23
|
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
|
Gan To Kagaku Ryoho
|
2011
|
0.80
|
|
24
|
Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy.
|
J Gastrointest Oncol
|
2014
|
0.79
|
|
25
|
Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer.
|
Chin J Cancer
|
2016
|
0.77
|
|
26
|
[A case of effective chemotherapy using S-1 and CPT-11 following chemoradiotherapy with UFT and Leucovorin for unresectable advanced sigmoid colon cancer].
|
Gan To Kagaku Ryoho
|
2010
|
0.77
|
|
27
|
[A case of locally advanced sigmoid colon cancer treated with neoadjuvant chemoradiotherapy].
|
Gan To Kagaku Ryoho
|
2014
|
0.77
|
|
28
|
Successful downstaging of high rectal and recto-sigmoid cancer by neo-adjuvant chemo-radiotherapy.
|
Clin Med Oncol
|
2008
|
0.77
|